Quantity Sold
Quantity Sold
Quantity Sold
Quantity Sold
Solid 2025 financial performance: 5% revenue growth year-over-year to EGP 1.755 billion, with gross margins improving from 35% to 39%. International debt obligations honored in full and on time. Persistently high interest rates and volatile global markets drove interest expenses up sharply — the cost of debt was the dominant 2025 challenge, with a capital-structure review underway for 2026.
Solid 2025 result: +8% revenue growth YoY to EGP 308.8 million, nearly meeting budget. Continued shift of agricultural operations from diesel to solar, with the EBDA biodynamic transition now anchoring 40,146 farmers across 23 governorates.
The group’s standout performer in 2025: +27% YoY to EGP 1.27 billion, +5% above budget, with local sales growth of 38%. Expanded into UAE, France, Qatar, Germany, Jordan, and Malaysia; record e-commerce sales and new product categories.
Faced a challenging year: revenues of EGP 90.3 million, −24% YoY due to ongoing price regulation in Egypt’s pharmaceutical market. Notable product progress: launch of Sedaneurine sales and commencement of internal Nervapatex production.
Modest 2025 growth: +4% YoY to EGP 242.4 million. Q4 was particularly impacted by delayed shipments. Demeter and EoL certifications maintained; international customer base continues to broaden.
Strong textile year: +42% revenue growth vs the previous year. The Jane Goodall collaboration on the "Mr. H" toy monkey continues to distribute globally through Jane Goodall Institutes.
Alignment
Driving our economic engine toward regenerative practices, phase by phase.
Closing loops in agriculture, manufacturing, and packaging to eliminate waste.
Fostering transparent, fair value chains that connect farmers directly to consumers.
Reinvesting capital into sustainable development rather than extractive profit.
Empowering consumers to make choices that heal the earth and society.